PT  - JOURNAL ARTICLE
AU  - Claire, Camus
AU  - Guillaume, Penaranda
AU  - Hacène, Khiri
AU  - Sabine, Camiade
AU  - Lucie, Molet
AU  - Melissa, Lebsir
AU  - Anne, Plauzolles
AU  - Laurent, Chiche
AU  - Bernard, Blanc
AU  - Edwin, Quarello
AU  - Philippe, Halfon
TI  - Acceptability and efficacy of vaginal self-sampling for genital infection and bacterial vaginosis: A large, cross-sectional, non-inferiority trial
AID  - 10.1101/2021.01.05.21249269
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.05.21249269
4099  - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249269.short
4100  - http://medrxiv.org/content/early/2021/01/06/2021.01.05.21249269.full
AB  - Objective Screening for genital infection (GI), bacterial vaginosis (BV), sexually transmitted infection (STI) and asymptomatic carriage of group B streptococcus (GBS) in pregnant women is a common reason for medical appointments. Objectives were first to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling to screen for GIs, bacterial vaginosis (BV), STIs, and GBS asymptomatic carriage in pregnant women; second to determine the feasibility of vaginal self-sampling.Methods Vaginal self-sampling (VSS) and vaginal/cervical classical sampling (VCS) of 1027 women were collected by health care professionals and simultaneously carried out on each patient. Bacterial infection, yeast infection, Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma genitalium, Trichomonas vaginalis and Herpes simplex virus types were systematically screened in both paired VSS and VCS samples.Results Statistical tests supported the non-inferiority of VSS compared with VCS. Agreements between VCS and VSS remained high regardless of the type of studied infection. VSS had successful diagnostic performances, especially for Predictive negative value (PNV) (over 90%) for all studied infections. Most participants (84%) recommended the use of VSS.Conclusions This study remains the most exhaustive in screening for GI, BV, STI agents and asymptomatic GBS carriage. Given its efficacy and acceptability, VSS seems to be a viable alternative to classic physician sampling among women in the general population. This study provides evidence that vaginal self-sampling can be used as a universal specimen for detection of lower genital tract infections in women.Study Identification number ID-RCB 2014-A01250-4Competing Interest StatementThe authors have declared no competing interest.Clinical TrialID-RCB 2014-A01250-4Funding StatementThis work was supported by European Alphabio Laboratory and European Hospital of Marseille and two industrial companies, Roche Molecular Systems, Inc., and BioMerieux, for providing reagents. Roche Molecular Systems, Inc., supported Claire Camus for the preliminary presentation at the ECCMID congress 2017. The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing the report. The corresponding author had full access to all study data and had final responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This biomedical clinical study was authorised by the French competent authority (ANSM, www.ansm.sante.fr) and received the agreement of an ethics committee (CPP Sud Mediterranee I). The French national identification number of the study is ID-RCB 2014-A01250-47.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available to researchers who provide a methodologically sound proposal. Requests should be addressed by email to g.penaranda{at}alphabio.fr